

**BioLight reports investment agreement  
and a manufacturing agreement in the subsidiary DiagnosTear**

DiagnosTear raises about \$ 4 million at a value of over \$ 18 million.

DiagnosTear and Elcam Medical also signed a commercial manufacturing agreement, according to which Elcam Medical commits to worldwide commercial production.

BioLight, which manages and develops innovative solutions in the field of ophthalmology, reports today (October 18, 2020) that a final and binding agreement has been signed for an investment in the subsidiary DiagnosTear, according to which Elcam Medical will invest \$ 2.85 million in diagnostics, and BioLight will invest an additional \$ 1 million in DiagnosTear.

The investment will be made by purchasing ordinary shares in DiagnosTear, at a DiagnosTear value of approximately \$ 18.25 million, after the money. Upon completion of the said investment, BioLight is expected to hold approximately 76% and Elcam Medical hold approximately 16%, of the share capital of DiagnosTear (fully diluted).

Simultaneously with the signing of the investment agreement, Elcam and DiagnosTear will sign a commercial production agreement, according to which Elcam Medical will commit to DiagnosTear for worldwide commercial production of some components of Diagnostic product,

according to maximum output and pre-determined price, payment terms, quality control and other parameters.

### **About Elcam Medical**

Elcam Medical is an Israeli cooperative association owned by Kibbutz Baram, with extensive manufacturing and marketing activities and an international reputation in the field of development and production of products and components for medical use, as well as a provider of innovative solutions in the field of flow control. Elcam Medical has a division that deals with the field of self-injection. Elcam Medical employs about 600 people in Israel, Italy and the United States and supplies hundreds of millions of products every year and manufactures products for leading companies in the world, including: Medtronic, B Braun, Baxter and more.

### **About DiagnosTear and DiagnosTear Product**

DiagnosTear is engaged in the development and commercialization of TeaRx™ technology designed to diagnose diseases of the front of the eye by examining the composition of the tear fluid. At this stage, DiagnosTear is developing a product for the diagnosis, personalization and follow-up of treatment for dry eye syndrome based on TeaRx™ technology.